Market Closed -
Other stock markets
|
After market 16:02:10 | |||
159.8 USD | -2.28% | 160.4 | +0.38% |
05:26pm | BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating | MT |
02:52pm | Morgan Stanley Adjusts AbbVie's Price Target to $191 From $196 | MT |
Sales 2024 * | 55.07B 75.23B | Sales 2025 * | 57.92B 79.13B | Capitalization | 283B 386B |
---|---|---|---|---|---|
Net income 2024 * | 8.18B 11.18B | Net income 2025 * | 11.03B 15.07B | EV / Sales 2024 * | 6.1 x |
Net Debt 2024 * | 53.1B 72.54B | Net Debt 2025 * | 46.7B 63.8B | EV / Sales 2025 * | 5.69 x |
P/E ratio 2024 * |
30.5
x | P/E ratio 2025 * |
23.7
x | Employees | 50,000 |
Yield 2024 * |
3.88% | Yield 2025 * |
4.07% | Free-Float | 96.75% |
Latest transcript on AbbVie Inc.
1 day | -1.91% | ||
1 week | -5.62% | ||
Current month | -11.93% | ||
1 month | -11.52% | ||
3 months | -2.69% | ||
6 months | +11.93% | ||
Current year | +3.32% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Gonzalez
CEO | Chief Executive Officer | 70 | 12-12-31 |
Scott Reents
DFI | Director of Finance/CFO | 57 | 12-12-31 |
Robert Michael
PSD | President | 53 | 11-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 63 | 12-12-31 |
Edward Rapp
BRD | Director/Board Member | 66 | 12-12-31 |
Director/Board Member | 70 | 12-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 159.8 | -2.28% | 103 |
24-04-26 | 159.1 | -4.92% | 102,502 |
24-04-25 | 167.3 | -0.52% | 3,211 |
24-04-24 | 168.2 | -1.15% | 206,873 |
24-04-23 | 170.1 | +0.50% | 738,782 |
Delayed Quote London S.E., April 29, 2024 at 11:30 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.24% | 661B | |
+26.74% | 566B | |
-6.37% | 352B | |
+19.16% | 332B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.10% | 145B | |
-11.17% | 144B |
- Stock Market
- Equities
- ABBV Stock
- 0QCV Stock